ONCOLife Issues
Featured Articles
Trending Articles
Teclistamab plus Daratumumab Achieves an 83% Risk Reduction in R/R Multiple Myeloma
Clinical Trials | 10 December 2025
Ribociclib Maintains Long-Term Disease Control in HR+ HER2 Metastatic Breast Cancer
Clinical Trials | 9 December 2025
Lunsumio Combo Deliver High Response Rates in Follicular and Large B-Cell Lymphomas
ONCOLife | 8 December 2025
Enozertinib Shows Strong Systemic and CNS Activity in EGFR Exon 20+ NSC Lung Cancer
Clinical Trials | 6 December 2025
FDA Approves Durvalumab as First Perioperative Immunotherapy for GEJ Cancers
FDA & EMA | 26 November 2025
FDA Approves Keytruda–Padcev Combo as First Perioperative Treatment for Bladder Cancer
FDA & EMA | 24 November 2025
Sevabertinib Wins FDA Approval with Strong Responses in HER2+ NSC Lung Cancer
FDA & EMA | 20 November 2025
FDA Approves Epcoritamab-bysp as the First Bispecific Antibody for Follicular Lymphoma
FDA & EMA | 19 November 2025
FDA Approves Ziftomenib as a New Targeted Option for NPM1+ Acute Myeloid Leukemia
FDA & EMA | 14 November 2025
Radioligand Therapy Pluvicto Reduces Progression Risk by 28% in mHS Prostate Cancer
ONCOLife | 5 November 2025
Lenvatinib Plus Everolimus Improves Outcomes After PD-1 Failure in Kidney Cancer
ONCOLife | 6 November 2025
ctDNA Blood Test Guides Chemotherapy Decisions for Tailored Colon Cancer Treatment
ONCOLife
4 November 2025
Trodelvy Emerges as Potential New Standard for First-Line Metastatic TN Breast Cancer
ONCOLife
24 October 2025
ESMO’s Road Map for Safe and Effective Use of AI-LLMs in Cancer Care: 23 Rules from 20 Experts
AI
3 November 2025
Datroway Extends Survival by 5 Months in Metastatic Triple-Negative Breast Cancer
ONCOLife
21 October 2025
Lenvatinib Plus Pembrolizumab Delivers Durable 5-Year Survival in Endometrial Carcinoma
ONCOLife
20 October 2025
Disarming Prostate Cancer: Dual Enzyme Blockade Weakens Tumors and Boosts Drug Response
ONCOLife
14 October 2025
Molecular Trojan Horse: Peptide Nanotubes Offer a Path to Defeat Drug-Resistant Tumors
ONCOLife
13 October 2025
Reprogramming Cancer Cell Death: A New Immune-Based Strategy for Blood Cancers
ONCOLife
12 October 2025
In Vivo CAR T on the Horizon: BMS Acquires Orbital to Expand Cell Therapy Reach
Pharma
10 October 2025
AstraZeneca makes deal with Trump Admin to Cut Drug Prices 80% and Invest $50B in US
Pharma
11 October 2025
FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CS Cell Carcinoma
FDA & EMA
9 October 2025
Datroway Improves Survival in First-Line Treatment of Metastatic Triple- Breast Cancer
ONCOLife
6 October 2025